 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
8 News |  |
- || LX7101 / Lexicon Pharma, Recalbon (minodronic acid) / Ono Pharma, Glanatec (ripasudil) / Kowa
Review, Journal: Should we keep rocking? Portraits from targeting rho kinases in cancer. (Pubmed Central) - Aug 26, 2021
Alternatively, we highlight and discuss detrimental effects of ROCK inhibition provoked not only by the action on off-targets, but most importantly, by pro-survival effects on cancer stem cells, dormant cells, and circulating tumor cells, along with cell-context or microenvironment-dependent contradictory responses. Together these drawbacks represent a risk for cancer cell dissemination and metastasis after anti-ROCK intervention, a caveat that should concern scientists and clinicians.
- | LX7101 / Lexicon
Journal: Loss of the fragile X mental retardation protein causes aberrant differentiation in human neural progenitor cells. (Pubmed Central) - Oct 24, 2019
Interestingly, the aberrant expression of GFAP and the impaired firing was corrected by treatment with the protein kinase inhibitor LX7101. These findings underscore the modulatory roles of FMRP in human neurogenesis, and further demonstrate that the defective phenotype of FXS could be reversed at least partly by small molecule kinase inhibitors.
- |||| LX7101 / Lexicon Pharma
Trial completion: Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Jul 31, 2012
P1/2, N=63, Completed, Sponsor: Lexicon Pharmaceuticals
These findings underscore the modulatory roles of FMRP in human neurogenesis, and further demonstrate that the defective phenotype of FXS could be reversed at least partly by small molecule kinase inhibitors. Active, not recruiting --> Completed
- ||||| LX7101 / Lexicon Pharma
New P1/2 trial: Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Feb 5, 2012
P1/2, N=63, Completed, Sponsor: Lexicon Pharmaceuticals